Департамент клинических исследований

Департамент клинических исследований

Clinical trials department

Slider

Hours worked

17500 +

Protocols involved

20 +

Sponsors secured

10 +

Why pharmaceutical companies choose us?

Time efficiency

at all clinical trial stages

Professionalism

of the investigators and study coordinators team

Extensive experience

in conducting clinical trials

Specialization

of the department in clinical trials

Our approach

Four simple steps for a successful clinical trial start
Clinical trial feasibility study
Ethics assessment
Patient enrollment channels evaluation
Step-by-step trial planning

Our resources

We are all set for conducting top notch clinical trials

Referral sites

Referral sites network includes policlinics and hospitals

Local Ethics Committee

Meeting 2 times per month or as needed

Investigators team

A wide range of therapeutic areas

Patients home visits service

Home visitation services for patients are conducted strictly in line with industry standards

Modern equipment

Fully equipped study site

Subjects pool

Potential patients pool proprietary constantly updated database of over 20000 potential participants

"Big Pharma" trust us

If you are interested in a reliable partner for conducting top notch phase II-III clinical trials on a wide range of nosologies and still do not work with us, please contact us

News

Stay up to date
Third place in the world in terms of enrollment in a study on Crohn's disease

Congratulations to the AMAM Study team for retaining the 3rd place in recruitment in the world. Russia is in the top 5! Excellent completion of the patient recruitment period

Training for COPD leaders

The staff of the center took part in an educational event of Boehringer Ingelheim, where leading federal experts-pulmonologists shared new knowledge on the problem of diagnosis and treatment of Chronic Obstructive Pulmonary Disease.

A new study for the treatment of severe bronchial asthma

Our Site was invited to participate in a new clinical trial of a new medicine for the biological therapy of severe eosinophilic bronchial asthma, conducted by the pharmaceutical company GSK.

Our partners

Protagonist
Gilead
Mithra
PRA Health Sciences
Pfizer
Rusmo-AG
Sanofi
Abbvie
Icon
Astra Zeneca
Gedeon Richter
Cromos Pharma
PPD
X7 Research
Synteract
IQVIA
Biorasi | Built for Faster Clinical Trials
PSI
ALK
Galecto
SRG
Clinipas
Astellas
Janssen
JonsonAndJonson
OCT
Celgen
Bristol-Myers Squibb Company
Biogen